Table 2.
Main characteristics of the study population according to the presence of antibodies against HAdv-D36.
| Variables | HAdv-D36 (+) (11) | HAdv-D36 (−) (194) | p-Value |
|---|---|---|---|
| Clinical and biodemographic data | |||
| Age, years | 9.7 ± 1.01 | 10.4 ± 1.02 | 0.054 |
| Tanner Stage [1–2/3–5], % | 72.7 (8)/27.3 (3) | 66.2 (127)/33.9 (65) | 0.647 |
| Sex [M/F], % | 45.5 (5)/55.6 (6) | 49.5 (96)/50.5 (98) | 0.795 |
| Dyslipidemia % | 36.4 (4) | 38.2 (74) | 0.906 |
| SBP, mmHg | 107.7 ± 15.5 | 109.4 ± 18.7 | 0.864 |
| DBP, mmHg | 67.0 ± 18.4 | 61.2 ± 16.7 | 0.642 |
| Insulin Resistance, % | 0 (0) | 20.1 (39) | 0.029 |
| Anthropometric Parameters | |||
| BMI z-score | 1.12 ± 0.90 | 1.53 ± 0.97 | 0.174 |
| Body fat, % | 24.0 ± 7.5 | 28.8 ± 8.8 | 0.084 |
| Biochemical Parameters | |||
| Total cholesterol, mg/dL | 153.3 ± 17 | 154 ± 29 | 0.895 |
| Triglycerides, mg/dL | 99 ± 54 | 100 ± 69 | 0.953 |
| LDL Cholesterol, mg/dL | 88 ± 13 | 84 ± 24 | 0.346 |
| HDL Cholesterol, mg/dL | 46 ± 8 | 51 ± 14 | 0.063 |
| Non-HDL cholesterol, mg/Dl | 107 ± 13 | 103 ± 29 | 0.347 |
| VLDL cholesterol, mg/dL | 21 ± 12 | 20 ± 14 | 0.833 |
| Glucose, mg/dL | 83 ± 5 | 85 ± 7 | 0.134 |
| Insulin, μU/mL | 8.9 ± 4.7 | 14.4 ± 9.5 | 0.003 |
| HOMA-IR | 1.81 ± 0.86 | 3.07 ± 2.21 | 0.001 |
Note: The number of individuals is in parentheses. Individuals were grouped according to seropositivity against HAdv-D36 (HAdv-D36 (−) and HAdv-D36 (+) represent negative and positive serology, respectively). Categorical data are presented as a percentage and were compared using the chi-square test. Continuous variables are shown as mean ± standard deviation and were compared using a t-test or Mann–Whitney U test for parametric and nonparametric variables, respectively. SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; LDL: low-density lipoprotein; HDL: high-density lipoprotein; VLDL: very-low-density lipoprotein, HOMA-IR: resistance index insulin according to the homeostatic model.